Geneos Wealth Management Inc. Nektar Therapeutics Transaction History

Geneos Wealth Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $562 - $950	-185 Reduced 42.53%	250 $0
Q4 2021 Feb 09, 2022	SELL	$10.83 - $18.41 $1,083 - $1,841	-100 Reduced 18.69%	435 $5,000
Q4 2020 May 19, 2021	SELL	$15.77 - $19.03 $5,787 - $6,984	-367 Reduced 40.69%	535 $10,000
Q3 2019 Sep 07, 2021	SELL	$16.91 - $36.27 $2,536 - $5,440	-150 Reduced 14.26%	902 $16,000
Q2 2019 Sep 07, 2021	SELL	$31.0 - $36.3 $3,100 - $3,629	-100 Reduced 8.68%	1,052 $37,000
Q4 2018 Sep 07, 2021	SELL	$30.43 - $56.65 $2,434 - $4,532	-80 Reduced 6.49%	1,152 $38,000
Q2 2018 Sep 07, 2021	BUY	$46.25 - $104.45 $27,333 - $61,729	591 Added 92.2%	1,232 $60,000
Q1 2018 Sep 07, 2021	BUY	$57.4 - $108.44 $36,793 - $69,510	641 New	641 $68,000

153

131M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $154M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

Stay updated on Geneos Wealth Management Inc. with notifications on news.